

27. The method according to Claim 26, wherein said condition is characterized by the occurrence of sprouting.
28. The method according to Claim 26, wherein said condition is characterized by the occurrence of seizures.
29. The method according to Claim 26, wherein said condition is epilepsy.
30. The method according to Claim 29, wherein said method results in a decrease in seizure proneness.
31. The method according to Claim 26, wherein said host is a mammalian host.
32. A method of treating a host suffering from a pathological condition resulting at least in part from proteolysis of the extracellular domains of cell adhesion molecules resulting from excessive activity of glutamate receptors, said method comprising:
administering to said host an amount of a serine protease inhibitor effective to treat said host for said condition.
33. The method according to Claim 32, wherein said excessive activity results from hypoxia, head trauma or stroke.
34. The method according to Claim 32, wherein said host is a mammalian host.
35. A method of treating a host suffering from a pathological condition resulting at least in part from proteolysis of the extracellular domains of cell adhesion molecules resulting from exogenous tPA activity, said method comprising:
administering to said host an amount of a serine protease inhibitor effective to treat said host for said condition.

36. The method according to Claim 35, wherein said serine protease inhibitor is administered to said host after administration of exogenous tPA.
37. The method according to Claim 35, wherein said host is a mammalian host.
38. A method of preventing the onset of a pathological condition resulting at least in part from proteolysis of the extracellular domains of cell adhesion molecules, which method comprises:
administering to said host an amount of a serine protease inhibitor effective to prevent onset of said condition.
39. The method according to Claim 38, wherein said condition is characterized by the occurrence of sprouting.
40. The method according to Claim 38, wherein said condition is characterized by the occurrence of seizures.
41. The method according to Claim 38, wherein said condition is epilepsy.
42. The method according to Claim 38, wherein said host is a mammalian host. --

REMARKS UNDER 37 CFR § 1.111

Formal Matters

Claims 26 to 42 are pending after entry of the amendments set forth herein.

The Applicants respectfully request that the above amendments be entered and note that the claims are all directed to an elected invention, i.e., to methods of treating pathologies